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Introduction:

Methods:

The number of deaths attributed to synthetic
opioids has nearly tripled in the US from
1999 to 2014. Although there is limited
evidence regarding the effectiveness of
long-term opioid therapy for chronic pain, a
condition estimated to affect 11.2% of the
US adult population; opioids are often
prescribed for this reason in the outpatient
setting. The CDC has produced guidelines
regarding safe opioid prescribing methods,
however changes are also necessary within
clinic systems to improve the safety and
management of opioid prescriptions This is
particularly important in resident led clinics
where multiple providers often see patients
over the course of their care. Our quality
improvement (QI) project aimed to
standardize clinic workflow and
management of chronic opioid prescription
by implementing routine surveillance
screening and creating a new patient survey.
Providers were also encouraged to do the
following: 1) update problem lists, 2)
document specific surveillance dates and
signed agreements, and 3) utilize a pre-made
progress note template to address specific
concerns with chronic opioid use.

On 10/1/16 the QI group introduced the
following routine surveillance suggestions to
clinic: 1) requiring an annually signed
chronic pain agreement, 2) urine drug screen
(UDS) collection at least every 6 months, 3)
Controlled Substance Utilization Review
and Evaluation System (CURES) report
checked at every clinic visit. A template for
chronic pain visits was created and shared
with all clinic providers in an effort to
improve these measures. Data was collected
on clinic patients one year prior to
implementation of the QI group
interventions (10/1/15 - 10/1/16) and six
months after implementation (10/1/16 6/1/17). To identify patients on chronic
opioid therapy, an Epic report was
generated, which filtered for specific predetermined ICD-9 codes. Additionally, a
physical list was kept in clinic on which
providers would document the MRN and
visit date of a patient who was on chronic
opioid therapy. Eligible patients were
flagged for any of the following if occurred
during the collection time period: 1) pain
agreement signed in the past 1 year, 2)
weaning opiate therapy discussed, 3)
CURES report checked, 4) UDS screen
ordered in the past 6 months, 5) abnormal
UDS/CURES report documented, and 6)
alternate therapies discussed.
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Results:
Pre-intervention data was collected from
10/01/15 to 10/01/16 (n=56). Preintervention data showed the following:
25.4% of encounters had documentation of a
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pain agreement within the last year, 35.4%
of encounters documented that weaning was
discussed, 21.4% of encounters documented
that CURES was checked or mentioned, and
37.5% of encounters documented that a
screening UDS was performed within the
last six months. Of 39 patients with
documented UDS or CURES, 9 (23.0%) had
a documented abnormal report.
Post-intervention data was collected from
10/01/16 to 06/01/17 (n=37) and showed the
following: 72.2% of encounters documented
a pain agreement within the last year, 81.0%
of encounters documented a discussion of
weaning medications, 88.5% of encounters
documented that CURES was checked or
mentioned, and 80.5% of encounters had
documented that a screening UDS was
performed within the last 6 months. Of 27
post-intervention patients, 12 patients
(44.4%) had a documented abnormal UDS
or CURES.
There were statistically significant
differences in encounters documenting a
pain agreement within the last year
(p<0.001), encounters in which weaning was
discussed and documented (p<0.001),
encounters in which CURES was checked or
mentioned and documented (p<0.001), and
encounters in which there was
documentation that a screening UDS was
performed within the last six months
(p=0.001). There was not, however, a
statistically significant difference in the
percentage of encounters in which UDS or
CURES was abnormal (p=0.22).
Conclusions:
The QI intervention shows a statistically
significant increase in provider compliance
to a new clinic-specific standardized
workflow and management practice for
opioid prescriptions given to chronic opioid
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users. This, however, did not result in a
decrease in the number of patients with an
abnormal UDS or CURES though data was
only collected for a six-month period after
the intervention began.
The data was fully dependent upon
documentation by the provider, which
creates the possibility of introducing bias
into results. As compliance with the
progress note template increases, the degree
of error arising from the assumption of the
correlation of documentation and real
practice should decrease accordingly.
Primary care physicians are responsible for a
significant burden of opioid prescriptions.
Introducing a new opioid-centered clinic
template improved clinic workflow and
potentially may lead to safer prescribing
methods. These efforts reflect an effort to
minimize prescription opiate abuse. The
next steps in our QI project aims to evaluate
safety and efficacy by utilizing information
that will now be documented in every
chronic pain clinic visit, specifically
morphine equivalents, PEG scores,
concurrent benzodiazepine use, and
concomitant high risk diseases (alcohol
abuse, depression, anxiety).
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